In summary, this study provided preliminary evidence that ATXP might have downregulate the expression of MAP3K4 through the plasma exosome miR-199a-3p to further improve liver function and pathological injury in rats with liver cancer, which ultimately delayed the progression of liver cancer. This evidence concerns the gene MAP3K4 and liver cancer.